Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBS72S in Brain Metastases and Leptomeningeal Disease
NCT05305365Phase 2Active, not recruiting
- Sponsor
- Melanie Hayden Gephart
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of QBS10072S in brain metastasis (BM) and leptomeningeal disease (LMD) (4 cohorts), sponsored by Melanie Hayden Gephart. Primary endpoint: Overall Response Rate at 6 months. Started Aug 2022; status: active, not recruiting.
02
Drugs
QBS10072S
03
Conditions
brain metastasis (BM)leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT05305365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305365.